Moreover, this HSF1 cancer program was found to be very significantly and broadly associated with poor outcomes such as metastasis and death in breast cancer, whereby patient survival decreases dose dependently as HSF1 nuclear levels increase [65, 66]. This evidence concerns the gene HSF1 and breast cancer.